PercayAI Software Platform

THE PERCAYAI SOFTWARE PLATFORM

DESIGNED TO BE FUNDAMENTALLY DIFFERENT

PercayAI - Assertion Engine and Web Upda

SIMPLIFIED DATA FABRIC
Automated data assembly instead of manual curation of disparate data sources.

NO MODEL TRAINING REQUIRED
Ontology free; Works out of the box, no additional manual training needed.

TRANSLATABLE

Enable better mouse to human translations by finding conserved contextual biology, a game-changer contrary to simplistic gene to gene comparisons.

WORKS ACROSS ALL DISEASE AREAS
Singular model equally relevant and disease-agnostic, obviates the need to build multiple AI models to address multiple diseases.

FULLY INTEGRATED PLATFORM FOR ALL STAGES OF SCIENTIFIC DISCOVERY

Omics analysis

Enabled by CompBio

Analyze omics and multi-omics datasets to identify contextually similar biology using published biological literature.

Explore the most integral and contextually relevant biology underlying personal or public datasets and the sources driving each insight.

With one tool that works across all disease areas and avoids the limitations and bias of human-curated ontologies, get an interactive 3D visualization of your omics data.

Explore all biology

Enabled by BioExplorer

Auto-curate a 3D, interactive knowledge map that allows you to quickly search and review biology within or outside your area of expertise.

Use concept-level comparisons to identify interactions between targets and processes, diseases, drugs, and more.

Rank and compare

Enabled by the Assertion Engine

With our most advanced feature, make rapid comparison across many datasets with just a few clicks.

Identify animal model relevance to human disease states

Compare analyses across multiple time points to identify conserved biology

Identify mechanisms of action and druggable targets

Rapid comparisons across datasets

Get started with the PercayAI software platform today

See it in action

Testimonials

"With its ease of use and ability to generate novel insights, PercayAI software has become a routine part of our analysis pipeline for multi-omics datasets."

Michael Barratt, PhD

Executive Director, Laboratory of Dr. Jeffrey Gordon

Washington University School of Medicine in St. Louis

TODAY

1 in 10

Drugs that enter clinical trials make it to market across all indications¹

¹Center for Medical Research

>50%

Failure rate in Phase 2 and 3 clinical trials² because targets were not linked to disease³

²Harrison 2016 Nat Rev Drug Discovery

³Morgan et al 2018 Nat Rev Drug Discovery

THE FUTURE WITH PERCAYAI: ENHANCED EFFICACY

2x

What if we could get more qualified drugs into clinical trials?

Still not convinced?

Read what sets our tools apart

Want to see the platform in action?

Request a demo